Trial results

DUTCH Weight Control in Atrial Fibrillation Study

NCT06184633 on ClinicalTrials.gov · last registry update 2024-09-19

An unusually large phase 4: 280 participants, more than double the 72 typical for the stage. Its estimated completion date, 1 May 2026, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for atrial fibrillation — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P4

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Rijnstate Hospital

Sponsor type

Other

Enrollment

280

Started

2024-07-21

Primary completion

2026-05-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome

Conditions studied

Atrial Fibrillation · Obesity · Weight Loss

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.